BGC 200134

Drug Profile

BGC 200134

Alternative Names: BGC-200134; Pleneva

Latest Information Update: 21 Mar 2014

Price : $50

At a glance

  • Originator BTG
  • Class Lipids
  • Mechanism of Action Transforming growth factor beta1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 01 Dec 2013 Discontinued - Phase-II for Multiple sclerosis in Spain (PO)
  • 01 Dec 2013 Discontinued - Phase-II for Multiple sclerosis in Poland (PO)
  • 01 Dec 2013 Discontinued - Phase-II for Multiple sclerosis in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top